Journal profile · Cardiac & Cardiovascular Systems
Journal of Cardiovascular Pharmacology
ISSN 0160-2446 · eISSN 1533-4023 · Lippincott Williams and Wilkins Ltd. · UNITED STATES · Monthly · Founded 1979
Journal of Cardiovascular Pharmacology: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.45; JCR Q2 (journal website); hybrid open access; median 132 days to acceptance (69 articles, last 24 months); community-reported acceptance: about 97.5%; 121 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Journal of Cardiovascular Pharmacology is published by Lippincott Williams and Wilkins Ltd. and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Nitric Oxide and Endothelin Effects, Cardiac electrophysiology and arrhythmias and Blood Pressure and Hypertension Studies, together about 32.1% of its articles. Its main subfields are Cardiology and Cardiovascular Medicine. (generated from OpenAlex topic counts and CAS ranking data)
Journal of Cardiovascular Pharmacology is a peer reviewed, multidisciplinary journal that publishes original articles and pertinent review articles on basic and clinical aspects of cardiovascular pharmacology. The Journal encourages submission in all aspects of cardiovascular pharmacology/medicine including, but not limited to: stroke, kidney disease, lipid disorders, diabetes, systemic and pulmonary hypertension, cancer angiogenesis, neural and hormonal control of the circulation, sepsis, neurodegenerative diseases with a vascular component, cardiac and vascular remodeling, heart failure, angina, anticoagulants/antiplatelet agents, drugs/agents that affect vascular smooth muscle, and arrhythmias. Appropriate subjects include new drug development and evaluation, physiological and pharmacological bases of drug action, metabolism, drug interactions and side effects, application of drugs to gain novel insights into physiology or pathological conditions, clinical results with new and established agents, and novel methods. The focus is on pharmacology in its broadest applications, incorporating not only traditional approaches, but new approaches to the development of pharmacological agents and the prevention and treatment of cardiovascular diseases. Please note that JCVP does not publish work based on biological extracts of mixed and uncertain chemical composition or unknown concentration.
Source: LetPub
Research area (LetPub): Cardiac & Cardiovascular Systems
Editor-in-chief George W. BoozPublisher website
Main research topics OpenAlex counts of recent articles; shares are approximate
- Nitric Oxide and Endothelin EffectsMedicine12.8%
- Cardiac electrophysiology and arrhythmiasMedicine11.6%
- Blood Pressure and Hypertension StudiesMedicine7.8%
- Receptor Mechanisms and SignalingBiochemistry, Genetics and Molecular Biology7%
- Renin-Angiotensin System StudiesMedicine5.5%
- Cardiac Ischemia and ReperfusionMedicine5.3%
- Hormonal Regulation and HypertensionMedicine5%
- Ion channel regulation and functionBiochemistry, Genetics and Molecular Biology4.9%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Cardiac & Cardiovascular Systems | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Cardiac & Cardiovascular Systems | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Cardiac & Cardiovascular Systems | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
JCR / CiteScore quartiles on the journal's website
- JCR Q2 · CARDIAC & CARDIOVASCULAR SYSTEMS · rank 111/237
- JCR Q3 · PHARMACOLOGY & PHARMACY · rank 205/356
Publisher-reported: JCR figures are Clarivate's and CiteScore figures Scopus's to confirm; both are a different system from the CAS zones.Publisher website
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.45LetPub ·
- Impact factor (publisher)
- 2.5Publisher website ·
- CiteScore 2026-06
- 4.6LetPub ·
- SJR 2026-06
- 0.68LetPub ·
- SNIP 2026-06
- 0.53LetPub ·
- h-index
- 91LetPub ·
- h-index
- 147OpenAlex ·
- i10-index
- 8,046OpenAlex ·
- 2-year mean citedness
- 2.36OpenAlex ·
- Self-citation rate
- 4%LetPub ·
- Share of gold OA articles
- 15.89%LetPub ·
Volume
- Articles per year
- 101LetPub ·
Articles by year OpenAlex count · 15,654 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 92 | 23 | 23 |
| 2025 | 121 | 24 | 271 |
| 2024 | 132 | 21 | 520 |
| 2023 | 145 | 43 | 924 |
| 2022 | 182 | 50 | 1,453 |
| 2021 | 229 | 42 | 2,837 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
132 daysMedian, submission to acceptance · P25–P75 78 days – 189 days
- Acceptance to online
- median 80 days (53 articles)
- Submission to online
- median 226 days
- Sample
- 69 articles with submission and acceptance dates (254 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 1 monthLetPub ·
- Average acceptance (community reports)
- 97.5%LetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
No source has fee information yet; check the journal's website.
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Lippincott Williams and Wilkins Ltd.
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Monthly
- Founded
- 1979
- ISSN
- 0160-2446
- Electronic ISSN
- 1533-4023
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
FAQ
Frequently asked questions about Journal of Cardiovascular Pharmacology
What CAS zone is Journal of Cardiovascular Pharmacology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Journal of Cardiovascular Pharmacology is in Zone 4 of Medicine, and in Zone 4 of the minor category Cardiac & Cardiovascular Systems / Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Journal of Cardiovascular Pharmacology?
The latest impact factor listed by LetPub is 2.45; CiteScore 4.6, h-index 147.
How long does peer review take at Journal of Cardiovascular Pharmacology?
Based on the dates recorded on 69 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 132 days (interquartile range 78–189 days); authors report an average review time of about 1 month; the community-reported acceptance is “about 97.5%”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What JCR quartile is Journal of Cardiovascular Pharmacology in?
The journal's website gives JCR Q2; by category, CARDIAC & CARDIOVASCULAR SYSTEMS Q2 (111/237), PHARMACOLOGY & PHARMACY Q3 (205/356). JCR quartiles are Clarivate's to confirm and a different system from the CAS zones; in the CAS ranking the journal is in Zone 4 of Medicine.
Which databases index Journal of Cardiovascular Pharmacology?
According to LetPub and DOAJ records, Journal of Cardiovascular Pharmacology is indexed in SCIE and Scopus.
Is Journal of Cardiovascular Pharmacology open access, and what is the APC?
Journal of Cardiovascular Pharmacology is a hybrid journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .